NEW YORK, July 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Allarity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On February 6 ...

Allarity Therapeutics (NASDAQ:ALLR) stock is on the rise Wednesday as the clinical-stage biopharmaceutical company is encouraging its shareholders to vote in favor of a reverse stock split.Allarity Therapeutics put out a press release pushing for investors to approve the reverse stock split during an upcoming shareholder meeting. That meeting is set to take place on Friday.Allarity Therapeutics is also advising its investors to approve the reduction of its authorized shares alongside the reverse stock split ...

ATLANTA, July 24, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR) complied with federal securities laws. On July 22, 2024, Allarity disclosed that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021." Followin ...

Boston (July 24, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, encourages its stockholders to participate actively in the upcoming annual meeting of stockholders scheduled on July 26, 2024. The Company's Board of Directors has put a proposal before stockholders for a reverse stock split. Allarity has requested approval of the reverse stock split to regain and sustain compl ...

  Current Cash Balance of $20 million Expected to Provide Runway Into 2026Allarity to Pause Use of ATMCap Table Successfully Cleaned UpAllarity's Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit Boston (July 22, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today outlines the Company's progress in 2024 and future objectives. Led by New Management Allarity has ...

  Current Cash Balance of $20 million Expected to Provide Runway Into 2026Allarity to Pause Use of ATMCap Table Successfully Cleaned UpAllarity’s Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit Boston (July 22, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today outlines the Company’s progress in 2024 and future objectives. Led by New Management Allarity ha ...

Boston (June 27, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it received notice from the NASDAQ Stock Market ("NASDAQ") that it was granted a hearing before a Nasdaq Hearings Panel (the "Panel"). This upcoming hearing, occurring in approximately 5 weeks, is scheduled for the Company to present its plan for regaining compliance following Nasdaq's no ...

Boston (May 20, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it has received formal written notice from The Nasdaq Stock Market, LLC's Office of General Counsel ("Nasdaq") that the Company has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). This confirmation foll ...

Exhibit 99.1 Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances - Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding, - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 87-2147982 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRA ...